Return to search results.
Complete title: Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 years of Age with Untreated High Risk (secondary) AML
|Research Study Number||2651.00|
|Principal Investigator||John Pagel, MD, PhD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Acute Myeloid Leukemia (AML); Hematologic Malignancies
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.